Ticker Details
Arbutus Biopharma Corporation Arbutus Biopharma Corp is a biopharmaceutical business engaged in advancing novel RNA interference therapeutics and discovering, developing and commercializing a cure for patients suffering from chronic hepatitis B infection.
IPO Date:	October 31, 2008
Sector:	Healthcare
Industry:	Biotech
Market Cap:	$821.22M
Activated in VL:	True

Average Daily Range
Avg Daily Range:	$0.12 | 3.25%
Avg Daily Range (30 D):	$0.12 | 2.81%
Avg Daily Range (90 D):	$0.11 | 2.40%

Institutional Daily Volume
Avg Daily Volume:	1.21M
Avg Daily Volume (30 D):	1.69M
Avg Daily Volume (90 D):	1.21M

Trade Size
Avg Trade Size (Sh.):	212
Avg Trade Size (Sh.) (30 D):	154
Avg Trade Size (Sh.) (90 D):	127

Institutional Trades
Total Institutional Trades:	299
Avg Institutional Trade:	$1.54M
Avg Institutional Trade (30 D):	$.72M
Avg Institutional Trade (90 D):	$1.07M
Avg Institutional Trade Volume:	.44M
Avg Institutional Trades (Per Day):	1

Market Closing Trades
Avg Closing Trade:	$1.74M
Avg Closing Trade (30 D):	$.73M
Avg Closing Trade (90 D):	$.98M
Avg Closing Volume:	471.26K

News

Feb 20, 2025 @ 8:22 AM Will Moderna Stock Drop to $25? 1 Wall Street Anal... Source: Eric Volkman

Jun 13, 2024 @ 9:12 AM Ultragenyx (RARE) Moves 7.8% Higher: Will This Str... Source: Zacks Equity Research

Jun 6, 2024 @ 3:15 PM Treatment with Arbutus’ Imdusiran and VTP-3... Source: Arbutus Biopharma Corporation

Jun 5, 2024 @ 6:30 AM Arbutus’ Imdusiran with Short Course Interf... Source: Arbutus Biopharma Corporation

May 29, 2024 @ 11:30 AM Arbutus to Participate in Jefferies Global Healthc... Source: Arbutus Biopharma Corporation

Financials
	TTM	Q3 2025	Q2 2025
Basic EPS	$-.23	$-.04	$.01
Diluted EPS	$-.23	$-.04	$.01
Revenue	$14.61M	$.53M	$10.74M
Gross Profit
Net Income / Loss	$-42.28M	$-7.74M	$2.52M
Operating Income / Loss	$-46.8M	$-8.66M	$1.49M
Cost of Revenue
Net Cash Flow	$-9.44M	$-15M	$.34M
PE Ratio

Splits
Nov 04, 2010	1:5